Photo: News 18

DCGI Grants EUA For 2 Doses Of ZyCoV-D, COVID Vaccine For Children

The Drugs Controller General of India granted Emergency Use Authorization (EUA) of two doses of ZyCoV-D, a COVID-19 vaccine for children above 12 years old. Manufactured by Zydus Lifesciences limited, the vaccine was used in three doses, for 0,28, and 56 days. However, with the recent approval, ZyCoV-D would now be used in two doses, with a gap of 0-28 days. With this, vaccination time required will be reduced.

Wed, 27 Apr 2022 - 10:13 AM / by Varsha Joshi

Tags: ZyCoV-D Vaccine, Covid-19 Vaccine, DCGI, children, Time Gap

Courtesy: ANI

DCGI Approves vaccine for children

Photo: The Times Of India

DCGI Approves Covaxin For Children Between 6-12 Year Old, Corbevax For EUA

The Drugs Controller General of India (DCGI) approved the two vaccines Covaxin and Corbevax for children under 12 in India, against COVID-19. While Bharat Biotech's Covaxin has been approved for 6 to12-year-old, Biological E's Corbevax will be used as Emergency Use Authorization (EUA) for 5 to12-year-old kids in India. The approval was based on the Subject Expert Committee's recommendation report, which was prepared as per trials of the… read-more

Tue, 26 Apr 2022 - 04:23 PM / by Varsha Joshi

Tags: Covaxin, covid-19 vaccines, DCGI, Corbevax, children


Photo: Hindustan Times

SEC Recommends Corbevax COVID-19 Vaccine For 5-12 Year Old

The Subject Expert Committee (SEC) or the Drugs Controller General of India (DCGI) recommended the Corbevax COVID-19 vaccine for children between the 5 to 12-year-old age group. On April 21, the government panel said the vaccine is effective in children and has been recommended after trials. Furthermore, the final approval for the emergency use authorization (EUA) of  Corbevax would be given by the DCGI soon.

Fri, 22 Apr 2022 - 11:00 AM / by Varsha Joshi

Tags: Corbevax, Covid-19, DCGI, Delhi, children

Courtesy: ANI

Nitric oxide nasal spray

Photo: ABP News

Glenmark Launches Nitric Oxide Nasal Spray For COVID-19 Patients In India

Amid COVID-19 pandemic, India is to have Nitric Oxide Nasal Spray, for adults having the infection. Launched on February 9 by Glenmark Pharmaceutical, the spray would be for adults, contracting the virus, with high-risk of progression of the disease. The medicine has been launched under FabiSpray brand in India. In July 2021, Glenmark proposed the nasal Spray, which later got approved by the Drugs Controller Genera of India (DCGI). 

Wed, 09 Feb 2022 - 10:35 AM / by Varsha Joshi

Tags: Covid-19, Nasal Spray, glenmark pharmaceuticals, Central Government, DCGI

mRNA vaccine

Photo: Hindustan Times

Human Trials Of mRNA, India's Vaccine Against Omicron To Begin In February

Human trials of mRNA vaccine against COVID-19's new variant Omicron is to begin from February. Notably, Pune-based Gennova Biopharmaceutical made mRNA vaccine and completed phase I and II trials and submitted a report to the Drugs Controller General of India (DCGI). Along with it, the company also submitted a data of Phase III trials and are waiting for their approval from the Vaccine Subject Expert Committee (SEC).

Mon, 17 Jan 2022 - 06:50 PM / by Varsha Joshi

Tags: mRNA, Omicron Vaccine, Gennova biopharmaceutical, Covid-19, DCGI

Courtesy: The Times Of India

Director Controller General of India

Photo: The Statesman

DCGI Approves India Made RT-PCR Kit To Detect Omicron

The Director Controller General of India (DCGI) approved India made RT-PCR kit to detect new COVID-19 variant "Omicron".  On January 5, ICMR General Director Dr Balram Bhagava said, the new RT-PCR kit has been manufactured by Tata MD and ICMR, to test Omicron. "This kit test will give results in four hours," said Dr. Bhagava. Meanwhile, in India, there are a total of 2,135 Omicron cases. 

Wed, 05 Jan 2022 - 06:51 PM / by Varsha Joshi

Tags: omicron, DCGI, ICMR, Dr Balram Bhargav, RT-PCR Kit

Courtesy: ANI

Bharat Biotech

Photo: Bharat Biotech Website

DCGI Approves Phase III Trial Of Bharat Biotech's Intranasal COVID-19 Vaccine

The Director Control General of India (DCGI) approved phase III trial of Intranasal COVID-19 vaccine, manufactured by Bharat Biotech. On January 4, the Subject Expert Committee (SEC) of the DCGI, approved the report, following which phase III trail will begin on 5,000 subject, 50% Covishield vaccinated people and 50% COVAXIN vaccinated people. If successful, the Intranasal vaccine will be used as booster shot, especially when nation is facing… read-more

Wed, 05 Jan 2022 - 01:48 PM / by Varsha Joshi

Tags: Bharat biotech, DCGI, Intranasal vaccine, Covid-19, omicron

Courtesy: One India


Photo: Business Standard

DCGI Gives Nod To Bharat Biotech For Administering Covaxin To Kids

Hyderabad-based Bharat Biotech was granted emergency approval to administer the COVID-19 vaccine to kids between the age of 12 to 18 years by the Drug Controller General of India (DCGI), on December 25. Reportedly, the company has further started the regulatory process to make it available on CoWin platform. Biotech's vaccine has become the second vaccine to receive approval after Zydus Cadila's three-dose needle-free vaccine ZyCoV-D in India… read-more

Sun, 26 Dec 2021 - 09:02 AM / by Brijesh Goswami

Tags: Covaxin, Bharat biotech, DCGI, approval, kids

Courtesy: Money Control

Bharat Biotech

Photo: The Economic Times

Hyderabad's Bharat Biotech Seeks Phase 3 Trial Of Intranasal Vaccine Booster Shot

Hyderabad based Bharat Biotech, on December 20, sough approval for phase 3 trial of its COVID-19 booster shot. The company urged the DCGI to approve trials for intranasal vaccine against COVID-19, especially amid Omicron scare. "The application has been filed and the company is awaiting approval from the drug regulator," reported PTI.  Notably, the company already conducted phase I and phase II trials and submitted a detailed report… read-more

Tue, 21 Dec 2021 - 11:22 AM / by Varsha Joshi

Tags: Intranasal vaccine, Covid-19, Bharat biotech, DCGI, Omicron Strain

Courtesy: The Indian Express


Photo: Firstpost

Bharat Biotech Awaits Approval To Roll Out Covaxin To Children Aged 2-8 Yrs

Bharat Biotech after submitting vaccine trial reports of "Covaxin" amongst beneficiaries aged between 2-8 years, said that they are awaiting the approval from the drug regulators. Upon receiving approval, Covaxin will become "one of the first vaccines in the world" to be administered to beneficiaries belonging to the said age group. After reviewing the results, the Subject Expert Committee (SEC) recommended the grant of the vaccine.

Tue, 12 Oct 2021 - 09:02 PM / by Shibu Immanuel S

Tags: Bharat biotech, Covaxin, DCGI, Vaccine Trial

Courtesy: ANI News